These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 18023583)
1. Reducing the risk of bone loss associated with breast cancer treatment. Hadji P Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583 [TBL] [Abstract][Full Text] [Related]
2. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Hadji P; Bundred N Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489 [TBL] [Abstract][Full Text] [Related]
3. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Brufsky A Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272 [TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA; Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735 [TBL] [Abstract][Full Text] [Related]
5. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009 [TBL] [Abstract][Full Text] [Related]
7. Management of bone loss induced by aromatase inhibitors. Gnant M Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162 [TBL] [Abstract][Full Text] [Related]
8. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185 [TBL] [Abstract][Full Text] [Related]
9. Prevention of osteoporosis after breast cancer. Reid DM Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826 [TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387 [TBL] [Abstract][Full Text] [Related]
11. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101 [TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R; J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195 [TBL] [Abstract][Full Text] [Related]
13. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. Ghazi M; Roux C Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692 [TBL] [Abstract][Full Text] [Related]
14. Long-term implications of bone loss in breast cancer. Aapro MS Breast; 2004 Dec; 13 Suppl 1():S29-37. PubMed ID: 15585380 [TBL] [Abstract][Full Text] [Related]
15. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment. Rozenberg S; Carly B; Liebens F; Antoine C Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824 [TBL] [Abstract][Full Text] [Related]
16. Cancer treatment-induced bone loss in breast and prostate cancer. Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443 [TBL] [Abstract][Full Text] [Related]
17. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Brufsky AM Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064 [TBL] [Abstract][Full Text] [Related]
18. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R; Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003 [TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Hadji P Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208 [TBL] [Abstract][Full Text] [Related]
20. Practical guidance for the management of aromatase inhibitor-associated bone loss. Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]